A comprehensive view of Weight Management Products. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer packaged goods (CPG) Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

GlobalData predicts GLP-1 drugs will redefine big pharma sales; Eli Lilly's diabetes drug, Mounjaro, is forecasted to generate US$34.0B by 2029, surpassing the entire 2023 portfolio of Lilly, with the Alzheimer's drug donanemab adding another US$5.0B
Published: April 17, 2024 by FiercePharma
Eli Lilly proposes revisions to FDA guidance addressing obesity, identifying obesity as a chronic disease and requesting updated practices for clinical trials to better address the growing public health crisis
Published: April 12, 2024 by Targeted News Service
Commentary: Excessive costs on GLP-1 medications from Eli Lilly and Novo Nordisk have led to their inaccessibility in low-/middle-income nations; report finds if branded companies were to partner with generics makers, prices could be less than US$1/month
Published: April 08, 2024 by Indian Pharma Industry: Policies
Argus downgrades PepsiCo to hold on concerns that increased product prices may decelerate revenue growth; popularity of weight-loss drugs, growing preference toward healthier options could decrease demand for PepsiCo's salty snacks, sweet drinks
Published: April 08, 2024 by Investing.com
Executive Perspective: Danone CEO Antoine de Saint-Affrique is optimistic about what the skyrocketing demand for GLP-1 weight loss drugs could mean for his company, saying: 'We see ourselves as extremely complementary to GLP-1s'
Published: April 04, 2024 by Quartz

Ask us about our Consumer packaged goods (CPG) market view

Trending Chart

Interactive chart with headline count